环孢素治疗掌跖脓疱病

目的：评价小剂量［１．２５～５ｍｇ／（ｋｇ·ｄ）］环孢素（ｃｙｃｌｏｓｐｏｒｉｎｅ）治疗掌跖脓疱病（ｐａｌｍｏｐｌａｎｔａｒｐｕｓｔｕｌｏｓｉｓ，ＰＰＰ）的效果。方法：４０例患ＰＰＰ病人，年龄４３±ｓ１３ａ（１７～７０ａ），随机分为环孢素组和安慰剂组各２０例。第１阶段口服环孢素２．５ｍｇ／（ｋｇ·ｄ）或安慰剂，ｂｉｄ，共４ｗｋ。第２阶段进行开放研究，４０例病人在１２ｗｋ内口服环孢素１．２５，２．５，３．７５，或５ｍｇ／（ｋｇ·ｄ）。第３阶段为停药后随访８ｗｋ以上。结果：经第２阶段１．２５ｍｇ／（ｋｇ·ｄ）治疗，治愈率１８％（２／１１），有效率３６％（４／１１），复发率４５％（５／１１）。经２．５ｍｇ／（ｋｇ·ｄ）治疗，治愈率６７％（１４／２１），有效率１９％（４／２１），复发率１４％（３／２１）。３．７５和５ｍｇ／（ｋｇ·ｄ）的治愈率分别为６７％（４／６）和１００％（２／２）。结论：环孢素治疗ＰＰＰ有效，且不良反应少。     

人生长激素治疗垂体性侏儒症的效力及安全性评价

目的：对生物合成人生长激素（ｈＧＨ）治疗垂体性侏儒症的效力及安全性进行评价。方法：垂体性侏儒症１６例，男性，其中１２例年龄１１±ｓ３ａ（７～１５ａ），骨龄５±３ａ（２～１０ａ），４例年龄１８．０±１．４ａ（１６～１９ａ），骨龄１２．７±１．２ａ（１１～１４ａ）。给予ｈＧＨ，每日剂量０．１ＩＵ／（ｋｇ·ｄ），ｓｃ，６～１２ｍｏ。结果：骨龄≤１１ａ的年身高增长速率１１．０±１．２ｃｍ（Ｐ＜０．０５），骨龄＞１１ａ的年身高增长速率１０．０±１．０ｃｍ（Ｐ＜０．０５），副作用少，治疗期对血液生化无不良影响。结论：ｈＧＨ对垂体性侏儒症的治疗效果满意，安全性好。     

人生长激素治疗垂体性侏儒症的效力及安全性评价

目的：对生物合成人生长激素（ｈＧＨ）治疗垂体性侏儒症的效力及安全性进行评价。方法：垂体性侏儒症１６例，男性，其中１２例年龄１１±ｓ３ａ（７￣１５ａ），骨龄５±３ａ（２￣１０ａ），４例年龄１８．０±１．４ａ（１６￣１９ａ），骨龄１２．７±１．２ａ（１１￣１４ａ）。给予ｈＧＨ，每日剂量０．１ＩＵ／（ｋｇ·ｄ），ｓｃ，６￣１２ｍｏ。结果：骨龄≤１１ａ的年身高增长速率１１．０±１．２ｃｍ（Ｐ〈０．０５），     

异维A酸治疗寻常痤疮疗效观察

寻常痤疮４４例，随机双盲分为Ａ和Ｂ２组。Ａ组１９例：男性１１例，女性８例，年龄２２±ｓ４ａ，服精制豆油胶丸，１０ｍｇ／丸，２－３丸／ｄ×１２ｗｋ。Ｂ组２５例；男性２０例，女性５例，年龄２４±４ａ，服异维Ａ酸胶丸，１０ｍｇ／丸，２－３丸／ｄ×１２ｗｋ。结果：总有效率Ａ组为５％，Ｂ组为９２％，经Ｒｉｄｉｔ分析ｐ＜０．０５。异维Ａ酸主要不良反应为口干。     

环孢素治疗掌跖脓疱病

目的：评价小剂量环孢素治疗掌跖脓疱病的效果。方法：４０例患ＰＰＰ病人，年龄４３±ｓ１３ａ（１７￣７０ａ），随机分为环孢素组和安慰剂组各２０例。第１阶段口服环孢素２．５ｍｇ／（ｋｇ·ｄ）或安慰剂，ｂｉ，共４ｗｋ。第２阶段进行开放研究，４０例病人在１２ｗｋ内口服环孢素１．２５，２．５，３．７５，或５ｍｇ／（ｋｇ·ｄ）。第３阶段为停药后随访８ｗｋ以上。结果：经第２阶段１．２５ｍｇ／（ｋｇ·ｄ）治疗，治愈     

多烯康与阿昔洛韦比较治疗带状疱疹

目的：观察多烯康与阿昔洛韦治疗带状疱疹的疗效比较。方法：７８例带状疱疹病人随机分为多烯康治疗组，男性３０例，女性９例，年龄４０±ｓ２０ａ，多烯康胶丸１．３５ｇ，ｐｏ，ｔｉｄ×１０ｄ；阿昔洛韦对照组，男性２８例，女性１１例，年龄４１±２２ａ，阿昔洛韦０．２ｇ，ｑｉｄ×１０ｄ。结果：多烯康组和阿昔洛韦组的治愈例数、治愈天数、止痛天数分别为３９例，１１±３ｄ，３．８±１．２ｄ和３８例，１０．６±２．９ｄ，４．０±１．５ｄ，差异不显著（Ｐ＞０．０５）；毒副作用：多烯康组为１例（１／３９）少于阿昔洛韦组（８例，８／３９），差异显著（Ｐ＜０．０５）。结论：多烯康治疗带状疱疹有效，毒副作用少。     

异维A酸治疗寻常痤疮疗效观察

寻常痤疮４４例，随机双盲分为Ａ和Ｂ２组。Ａ组１９例，男性１１例，女性８例，年龄２２±ｓ４ａ服精制豆油胶丸，１０ｍｇ／丸，２－３丸／ｄ×１２ｗｋ。Ｂ组２５例；男 性２０例，女性５例，年龄２４±４ａ，服异维Ａ酸丸，１０ｍｇ／丸，２－３丸／ｄ×１２ｗｋ。结果：总有效率Ａ组为５％，Ｂ组为９２％，经Ｒｉｄｉｔ分析Ｐ＜０．０５。异维Ａ酸主要反应为口干。     

劳拉西泮与碳酸锂治疗躁狂症的比较

目的：评估劳拉西泮对躁狂症的疗效。方法：用劳拉西泮治疗男性躁狂症１９例（年龄２８±ｓ１０ａ，病程２．０±１．３ｍｏ），剂量６～１８ｍｇ／ｄ，疗程３ｗｋ，并与碳酸锂治疗男性躁狂症２０例（年龄２８±１１ａ，病程２．０±１．３ｍｏ）对照，剂量１．５～２．５ｇ／ｄ，疗程３ｗｋ。结果：劳拉西泮组，总有效率８９％，碳酸锂组，总有效率９５％（Ｐ＞０．０５），但劳拉西泮起效时间较碳酸锂为早，不良反应以嗜唾、头晕为主。结论：劳拉西泮可作为控制躁狂症急性发作的有效药物。     

肌内注射维生素K3对中重度高血压病的疗效

目的：观察维生素Ｋ３治疗高血压病的疗效。方法：２８例高血压病人（男性２１例，女性７例；年龄５５±ｓ１１ａ）交叉肌内注射维生素Ｋ３８ｍｇ和维生素Ｂ１１００ｍｇ各１次，观察用药前后３ｈ内的血压变化，其中１０例应用动态血压监测评价。结果：用维生素Ｋ３１．５ｈ时血压较用药前下降幅度与维生素Ｂ１相比差别非常显著（收缩压前者下降４．０±２．５，后者增加０．１±１．８ｋＰａ，Ｐ＜０．０１；舒张压前者下降２．４±１．８，后者增加０．３±１．４ｋＰａ，Ｐ＜０．０１）。结论：维生素Ｋ３降压有效，适用于伴发鼻出血，胆、肾绞痛的高血压病人     

山莨菪碱与苯丙醇胺加氯苯那敏治疗感冒的疗效比较

目的：观察山莨菪碱治疗感冒的效果。方法：感冒病人２１１例按单盲随机分成２组，Ａ组（１０７例，男性５１例，女性５６例，年龄３２±ｓ１１ａ）用山莨菪碱５～１０ｍｇ，ｐｏ，ｔｉｄ，３ｄ；Ｂ组（１０４例，男性４９例，女性５５例，年龄３５±９ａ）用复方盐酸苯丙醇胺缓释胶囊１粒，ｐｏ，ｂｉｄ，３ｄ。结果：显效率和总有效率，Ａ组是８６．９％和９６．２％；Ｂ组是５３．８％和６１．５％，Ｐ＜０．０５。结论：山莨菪碱治疗感冒明显优于复方盐酸苯丙醇胺缓释胶囊     

异维A酸治疗尖锐湿疣对白细胞介素-2、可溶性白细胞介素-2受体影响

目的 :观察异维A酸治疗尖锐湿疣对血清白细胞介素 2 (IL 2 ) ,可溶性白细胞介素 2受体(sIL 2R)的变化 ,以探讨异维A酸治疗尖锐湿疣的作用机制。方法 :3 2例尖锐湿疣病人 ,初发 1 3例 ,复发 1 9例 ,给异维A酸胶丸 1 0mg,po,tid或bid ,随访 3mo ,治疗前及治疗后mo 4查血清sIL 2R ,IL 2。结果 :痊愈 2 4例 (75 % ) ,显效 3例 ,有效 2例 ,无效 3例 (9% ) ;血清sIL 2R初发病人治疗前为(2 0 1±s 1 2 1 ) pmol·L-1,治疗后mo 4为 (1 93±1 3 2 ) pmol·L-1,P <0 .0 5 ;血清sIL 2R复发病人治疗前为 (693± 1 2 1 )pmol·L-1,治疗后mo 4为 (5 1 9± 1 0 3 ) pmol·L-1,P <0 .0 1 ;血清IL 2初发病人治疗前 (7.0± 1 .2 ) μg·L-1,治疗mo 4为 (7.2± 1 .2 )μg·L-1,P <0 .0 1 ;血清IL 2复发病人治疗前 (6±3 ) μg·L-1,治疗后mo 4为 (8.5± 2 .7) μg·L-1,P<0 .0 1。结论 :异维A酸通过调节免疫及其他多种机制达到治疗尖锐湿疣的作用     

The long-term effect of oral isotretinoin therapy on macula ganglion cell complex thickness

Purpose: To evaluate the long-term effect of oral isotretinoin therapy on macula ganglion cell complex (GCC) thickness by spectral domain optical coherence tomography (SD-OCT).

Materials and methods: Newly diagnosed cystic acne patients who received low dose for a long time systemic isotretinoin therapy were included in this study. Thorough ophthalmic evaluation and GCC thickness analysis by using SD-OCT were performed at baseline, and at 1, 3, 6, and 12 months of treatment.

Results: Forty-eight eyes of 24 patients (15 females, 9 males) were included in the study. The mean age of patients was 19.37?±?2.74 years (range 14–25 years). The full ophthalmologic examination was normal in all eyes before treatment. During the treatment there were no change in visual acuity, refractive error, intraocular pressure and tear break-up time. The mean GCC thicknesses were 81.45?±?4.91, 81.45?±?5.12, 81.81?±?4.68, 81.87?±?4.91 and 81.64?±?5.09?μm at pretreatment and at 1, 3, 6, and 12 months of treatment, respectively (p?=?0.803).

Conclusion: One-year systemic use of isotretinoin had no significant effect on the thickness of macula ganglion cell. Macular ganglion cell analysis is useful for determining and following the toxic effects of systemic drugs on the retina. However, it is more rational to consider it as an adjunct to electrophysiological testing rather than used alone.     

通心络对椎基底动脉系短暂性脑缺血发作病人血流动力学的影响

目的 :探讨通心络对椎 基底动脉系短暂性脑缺血发作 (TIA )病人血流动力学的影响。方法 :将 6 6例TIA病人年龄以 6 0a为界分为 2组 ,均服用通心络胶囊 4粒 (每粒 0 .38g) ,tid ,疗程 4wk。结果 :治疗前后TIA病人颅内椎动脉血流速度差值为左、右侧老年组为 (4± 11)cm·s- 1和 (4± 12 )cm·s- 1,青、中年组为 (5± 10 )cm·s- 1和 (5± 11)cm·s- 1;基底动脉血流速度差值老年人组为 (6± 15 )cm·s- 1,青、中年组为 (4± 10 )cm·s- 1(P <0 .0 5或<0 .0 1) ,且老年组脉动指数较治疗前显著降低 (P<0 .0 5 )。治疗期间无明显不良反应。结论 :通心络胶囊可减轻动脉硬化程度 ,改善脑供血 ,是治疗椎 基底动脉系TIA和预防缺血性卒中的有效药物     

Reduced central corneal thickness in patients with isotretinoin treatment

Context: It is well known that oral isotretinoin treatment causes numerous ocular side-effects.

Objective: To investigate the effect of systemic isotretinoin treatment on central corneal thickness (CCT) values due to meibomian gland disease (MGD).

Participants: In this prospective study, 47 patients (27 men, 20 women) with nodulocystic acne vulgaris treated with oral isotretinoin (0.8?mg/kg daily) were included.

Methods: All patients were analyzed with the Pentacam Scheimpflug topography at baseline, on the 3rd and 6th month of treatment. Main outcome measures were MGD scores and CCT.

Results: The mean age of patients was 25.1?±?4.4 years. The mean MGD scores were significantly higher at 3rd month (1.3?±?0.9) and 6th month (1.5?±?1.0) of treatment compared with baseline (1.1?±?0.9) (p?p?p?=?0.038, r?=??0.221).

Conclusion: Isotretinoin treatment causes higher MGD scores. A statistically significant decrease in CCT due to MGD was detected at 6th month of treatment.     

The effect of oral isotretinoin on visual contrast sensitivity and amount of lacrimation in patients with acne vulgaris

Context: Acne vulgaris is a puberty-onset chronic inflammatory disease of the pilosebaceous unit. Isotretinoin is a derivative of vitamin A commonly used for severe and nodulocystic acne. While isotretinoin has many side effects related to the eye, visual system and lacrimation, there is no information regarding isotretinoin’s influence on contrast sensitivity.

Aim: To investigate the effect of isotretinoin on visual contrast sensitivity and the amount of lacrimation.

Materials and methods: The study included 25 patients (16 females and 9 males) who underwent isotretinoin treatment. The treatment duration ranged from 4 to 7 months. Patients were examined both before the start and at the end of treatment using the Schirmer test in each eye. The contrast sensitivity measurement was performed both individually for each eye and in a binocular fashion using the Pelli–Robson Sensitivity Chart.

Results: The results of the Schirmer test before treatment were 19.74?±?3.63?mm for the right eye and 19.66?±?3.63?mm for the left eye. Post-treatment measurement results were 17.24?±?3.5?mm for the right eye and 16.68?±?3.73?mm for the left eye. There was a statistically significant difference between the before and after treatment measurements (p?<?0.000). Before treatment, contrast sensitivity was 1.45?±?0.19 for the right eye and 1.42?±?0.2 for the left eye. The binocular measurement was 1.54?±?0.14. After treatment, the right eye was 1.47?±?0.19, the left eye was 1.46?±?0.18, and the binocular measurement was 1.54?±?0.18. There were no statistically significant differences between before and after treatment (p?>?0.05).

Discussion: There are contradicting reports on the results of the Schirmer test. The only similar study that has evaluated contrast sensitivity used the drug acitretin, the results of which are consistent with those the present study.

Conclusion: Our study is significant in that it is the first to investigate the effects of isotretinoin on visual contrast sensitivity that is closely associated with real-world performance. Our results need to be supported by future studies.     

牛磺酸加泛癸利酮治疗病毒性心肌炎

目的：观察牛磺酸加泛癸利酮治疗病毒性心肌炎（ＶＭＣ）的疗效。方法：ＶＭＣ９５例在用泛癸利酮２０ｍｇ，ｐｏ，ｔｉｄ基础上分为３组：（１）加牛磺酸组３０例，给牛磺酸２ｇ，ｐｏ，ｔｉｄ；（２）加牛磺酸及抗心律失常药物组３０例，给牛磺酸服法同上，另外加普罗帕酮１５０ｍｇ，ｐｏ，ｔｉｄ或美西律１５０ｍｇ，ｐｏ，ｔｉｄ；（３）对照组３５例，给极化液（５％葡萄糖５００ｍＬ＋１０％氯化钾１０ｍＬ＋胰岛素８Ｕ）静脉滴注，ｑｄ×２ｗｋ后改用维生素Ｃ０．２ｇ，ｐｏ，ｔｉｄ。３组疗程依次为４．０±１．０ｍｏ，３．０±２．０ｍｏ及６±３ｍｏ。结果：临床症状、肠道病毒核糖核酸转阴率及早搏减少的总有效率，３组依次为８７％，７９％，９０％；９３％，７８％，９５％％；６３％，４３％，６０％。前２组优于对照组（Ｐ＜０．０５）。结论：牛磺酸加泛癸利酮对ＶＭＣ有较好疗效。